by Jordana Choucair | Feb 15, 2022 | Transition to Value
Provider groups are lobbying Congress and federal regulators to not revoke the Direct Contracting payment model, which allows providers to get capitated population-based payments. The efforts come amid concerns from progressive groups and lawmakers that most direct...
by Jordana Choucair | Feb 14, 2022 | D.C. News
More than 70 Republican lawmakers asked the Biden administration to end the federal public health emergency for COVID-19. In a letter to the administration, they state that “our country is now in a much different situation than we were when the PHE was...
by Jordana Choucair | Feb 14, 2022 | Life Sciences
The Federal Trade Commission will vote Thursday on whether it will study how pharmacy benefit managers (PBMs) affect drug prices and the businesses of pharmacies. The vote comes after years of pharmacies’ complaints over PBM fees for reimbursement, quality metrics,...
by Jordana Choucair | Feb 14, 2022 | Life Sciences
The FDA on Friday authorized a new monoclonal antibody treatment to treat mild to moderate COVID-19 symptoms. The drug, developed by Eli Lilly, should be used to treat patients ages 12 and older “for whom alternative COVID-19 treatment options approved or...
by Jordana Choucair | Feb 14, 2022 | Life Sciences
The FDA delayed its decision on authorizing Pfizer-BioNTech’s COVID-19 vaccine for children under five years old. The agency stated, “Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional...
by Jordana Choucair | Feb 14, 2022 | Payers
With Congress eyeing a comprehensive mental health package this year, the health insurance industry is pushing back against a pair of proposals to ramp up enforcement against plans that violate mental health parity laws by regularly denying behavioral health and...
Recent Comments